EW Q4 2025 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q4 2025 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.6B+13.3% YoY

Gross Profit

$1.2B78.3% margin

Operating Income

$370M23.6% margin

Net Income

$91M5.8% margin

EPS (Diluted)

$0.16

QoQ Revenue Growth

+1.1%

Cash Flow

Operating Cash Flow

$451M

Free Cash Flow

$354M

Stock-Based Comp.

$39M

Balance Sheet

Total Assets

$13.7B

Total Liabilities

$3.4B

Stockholders' Equity

$10.3B

Cash & Equivalents

$2.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.6B	$1.4B	+13.3%
Gross Profit	$1.2B	$1.1B	+12.4%
Operating Income	$370M	$313M	+18.5%
Net Income	$91M	$386M	-76.3%

Revenue Segments

Transcatheter Heart Valves

$1.2B74%

Surgical Heart Valve Therapy

$254M16%

Transcatheter Mitral And Tricuspid Therapies

$156M10%

Geographic Segments

UNITED STATES

$907M52%

Europe

$410M24%

Rest of World

$333M19%

JAPAN

$88M5%